Clinical value of 3'-deoxy-3'-[18F]fluorothymidine-positron emission tomography for diagnosis, staging and assessing therapy response in lung cancer

Bandar  Alwadani; Sergio Dall'Angelo; Ian Fleming

doi:10.1186/s13244-021-01026-1

Clinical value of 3'-deoxy-3'-[18F]fluorothymidine-positron emission tomography for diagnosis, staging and assessing therapy response in lung cancer

Bandar Alwadani, Sergio Dall'Angelo, Ian Fleming^* (Corresponding Author)

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

8 Citations (Scopus)

3 Downloads (Pure)

Abstract

Lung cancer has the highest mortality rate of any tumour type. The main driver of lung tumour growth and development is uncontrolled cellular proliferation. Poor patient outcomes are partly the result of the limited range of effective anti-cancer therapies available and partly due to the limited accuracy of biomarkers to report on cell proliferation rates in patients. Accordingly, accurate methods of diagnosing, staging and assessing response to therapy are crucial to improve patient outcomes. One effective way of assessing cell proliferation is to employ non-invasive evaluation using 3'-deoxy-3'-[18F]fluorothymidine ([18F]FLT) positron emission tomography [18F]FLT-PET. [18F]FLT, unlike the most commonly used PET tracer [18F]fluorodeoxyglucose ([18F]FDG), can specifically report on cell proliferation and does not accumulate in inflammatory cells. Therefore, this radiotracer could exhibit higher specificity in diagnosis and staging, along with more accurate monitoring of therapy response at early stages in the treatment cycle. This review summarises and evaluates published studies on the clinical use of [18F]FLT to diagnose, stage and assess response to therapy in lung cancer.

Original language	English
Article number	90
Number of pages	21
Journal	Insights into Imaging
Volume	12
Issue number	1
DOIs	https://doi.org/10.1186/s13244-021-01026-1
Publication status	Published - 2 Jul 2021

Bibliographical note

Funding
This review was supported by funding provided by the Royal Embassy of Saudi Arabia, Cultural Bureau in London, UK. We also gratefully acknowledge Friends of Anchor for their generous financial support of our research.
Availability of data and materials
The datasets used and/or analyses during the current study are available from the corresponding author upon reasonable request.

Keywords

Positron emission tomography
PET
Lung cancer
Fluorothymidine
[18F]FLT

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1186/s13244-021-01026-1Licence: CC BY

Alwadani_etal_IiI_Clinical_value_of_VOR
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Final published version, 1.36 MBLicence: CC BY

Cite this

@article{2f9747491f6b4a018642990a1151e37f,

title = "Clinical value of 3'-deoxy-3'-[18F]fluorothymidine-positron emission tomography for diagnosis, staging and assessing therapy response in lung cancer",

abstract = "Lung cancer has the highest mortality rate of any tumour type. The main driver of lung tumour growth and development is uncontrolled cellular proliferation. Poor patient outcomes are partly the result of the limited range of effective anti-cancer therapies available and partly due to the limited accuracy of biomarkers to report on cell proliferation rates in patients. Accordingly, accurate methods of diagnosing, staging and assessing response to therapy are crucial to improve patient outcomes. One effective way of assessing cell proliferation is to employ non-invasive evaluation using 3'-deoxy-3'-[18F]fluorothymidine ([18F]FLT) positron emission tomography [18F]FLT-PET. [18F]FLT, unlike the most commonly used PET tracer [18F]fluorodeoxyglucose ([18F]FDG), can specifically report on cell proliferation and does not accumulate in inflammatory cells. Therefore, this radiotracer could exhibit higher specificity in diagnosis and staging, along with more accurate monitoring of therapy response at early stages in the treatment cycle. This review summarises and evaluates published studies on the clinical use of [18F]FLT to diagnose, stage and assess response to therapy in lung cancer.",

keywords = "Positron emission tomography, PET, Lung cancer, Fluorothymidine, [18F]FLT",

author = "Bandar Alwadani and Sergio Dall'Angelo and Ian Fleming",

note = "Funding This review was supported by funding provided by the Royal Embassy of Saudi Arabia, Cultural Bureau in London, UK. We also gratefully acknowledge Friends of Anchor for their generous financial support of our research. Availability of data and materials The datasets used and/or analyses during the current study are available from the corresponding author upon reasonable request. ",

year = "2021",

month = jul,

day = "2",

doi = "10.1186/s13244-021-01026-1",

language = "English",

volume = "12",

journal = "Insights into Imaging",

issn = "1869-4101",

publisher = "Springer ",

number = "1",

}

TY - JOUR

T1 - Clinical value of 3'-deoxy-3'-[18F]fluorothymidine-positron emission tomography for diagnosis, staging and assessing therapy response in lung cancer

AU - Alwadani, Bandar

AU - Dall'Angelo, Sergio

AU - Fleming, Ian

N1 - Funding This review was supported by funding provided by the Royal Embassy of Saudi Arabia, Cultural Bureau in London, UK. We also gratefully acknowledge Friends of Anchor for their generous financial support of our research. Availability of data and materials The datasets used and/or analyses during the current study are available from the corresponding author upon reasonable request.

PY - 2021/7/2

Y1 - 2021/7/2

N2 - Lung cancer has the highest mortality rate of any tumour type. The main driver of lung tumour growth and development is uncontrolled cellular proliferation. Poor patient outcomes are partly the result of the limited range of effective anti-cancer therapies available and partly due to the limited accuracy of biomarkers to report on cell proliferation rates in patients. Accordingly, accurate methods of diagnosing, staging and assessing response to therapy are crucial to improve patient outcomes. One effective way of assessing cell proliferation is to employ non-invasive evaluation using 3'-deoxy-3'-[18F]fluorothymidine ([18F]FLT) positron emission tomography [18F]FLT-PET. [18F]FLT, unlike the most commonly used PET tracer [18F]fluorodeoxyglucose ([18F]FDG), can specifically report on cell proliferation and does not accumulate in inflammatory cells. Therefore, this radiotracer could exhibit higher specificity in diagnosis and staging, along with more accurate monitoring of therapy response at early stages in the treatment cycle. This review summarises and evaluates published studies on the clinical use of [18F]FLT to diagnose, stage and assess response to therapy in lung cancer.

AB - Lung cancer has the highest mortality rate of any tumour type. The main driver of lung tumour growth and development is uncontrolled cellular proliferation. Poor patient outcomes are partly the result of the limited range of effective anti-cancer therapies available and partly due to the limited accuracy of biomarkers to report on cell proliferation rates in patients. Accordingly, accurate methods of diagnosing, staging and assessing response to therapy are crucial to improve patient outcomes. One effective way of assessing cell proliferation is to employ non-invasive evaluation using 3'-deoxy-3'-[18F]fluorothymidine ([18F]FLT) positron emission tomography [18F]FLT-PET. [18F]FLT, unlike the most commonly used PET tracer [18F]fluorodeoxyglucose ([18F]FDG), can specifically report on cell proliferation and does not accumulate in inflammatory cells. Therefore, this radiotracer could exhibit higher specificity in diagnosis and staging, along with more accurate monitoring of therapy response at early stages in the treatment cycle. This review summarises and evaluates published studies on the clinical use of [18F]FLT to diagnose, stage and assess response to therapy in lung cancer.

KW - Positron emission tomography

KW - PET

KW - Lung cancer

KW - Fluorothymidine

KW - [18F]FLT

U2 - 10.1186/s13244-021-01026-1

DO - 10.1186/s13244-021-01026-1

M3 - Article

SN - 1869-4101

VL - 12

JO - Insights into Imaging

JF - Insights into Imaging

IS - 1

M1 - 90

ER -

Clinical value of 3'-deoxy-3'-[18F]fluorothymidine-positron emission tomography for diagnosis, staging and assessing therapy response in lung cancer

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this